Veeva's AI agents have five customers and no published price, and the stock already tops its $303.52 target
Amgen's global Vault CRM rollout and a Copenhagen summit full of agentic AI put Veeva's bull case on stage, but the agent product has five customers, no published price, and a stock already above the average analyst target.
Vincent Jiang · 2 min read
Amgen signs, the Summit sells, the price waits
Amgen−0.80% — Amgen, down 0.80 percent today, one of the world's largest biotech companies, said on October 27 that it will deploy Veeva's Vault CRM globally as the foundation of an "AI-enabled commercial technology foundation" 1. Three days later Veeva+0.22% — Veeva, up 0.22 percent today put its Copenhagen summit, November 18 to 19, on the calendar, with AstraZeneca, Roche, GSK and Bristol Myers Squibb−0.05% — Bristol Myers Squibb, down 0.05 percent today lined up to describe scaling agentic customer engagement: AI agents, software that acts on its own, doing work a sales representative used to do 2.
The bull case writes itself. Agents need a trusted, regulated system of record to act in, and Veeva sells that record.
The system of record grows. The agent does not.
Veeva's fiscal second quarter, ended July 31, 2026, brought revenue of $927.96 million, up 17.6% year over year, with GAAP operating income up 40% 3. Commercial subscription revenue rose 13%, more than 180 customers are live on Vault CRM, and Eli Lilly−0.58% — Eli Lilly, down 0.58 percent today and Biogen−1.44% — Biogen, down 1.44 percent today signed 4.
Falcon, Veeva's agentic labor product, has five early adopters, with first go-lives not expected until fiscal 2027 4. Veeva keeps 70% of its biopharma CRM subscription base 3. IQVIA−2.42% — IQVIA, down 2.42 percent today, the world's largest drug-trial operator, reports more than 400 AI agents already deployed, commercial organic growth doubled year over year, and a $2.1 billion adjustment after reviewing inactive trials in a $32.6 billion contract book 5. The agents are in production. The revenue line is not.
Revenue compounds at 16 to 18 percent; no AI step-change in the line yet
Data
| Revenue | |
|---|---|
| Q3 '24 | $699.21M |
| Q4 '24 | $720.89M |
| Q1 '25 | $759.04M |
| Q2 '25 | $789.08M |
| Q3 '25 | $811.24M |
| Q4 '25 | $835.95M |
| Q1 '26 | $882.95M |
| Q2 '26 | $927.96M |
No dollar, no retention, and the multiple already moved
Nothing Veeva has published names how an agent gets priced: per seat, per task or per piece of commercial evidence. That matters because an agent that makes the calls is what shrinks a seat count, and Veeva still sells seats. The market has pre-paid for the answer. The stock closed at $312.96 on October 30, above the $303.52 average target of the 28 analysts covering it, at 15.06 times trailing sales and 51.3 times trailing earnings, more than double its 52-week low of $148.05 7.
The November 5 test
The counterargument is real. CNBC frames Veeva as the picks-and-shovels way to play a biotech funding boom 8, and IQVIA, Veeva's onetime courtroom rival, made Veeva's clinical trial applications its enterprise standard on October 13 9. Veeva guided fiscal 2027 revenue growth to about 15% 3.
But that growth is already in the price. At the investor day on November 5, watch one thing: a dollar figure on the agentic layer, and a retention number that survives agents doing the work 7. If neither arrives, earnings land on November 25 7 and the multiple has moved without the revenue to hold it.
Get Applications by email, free
How AI is changing the software people and companies use. In our daily email, every weekday.
